{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:33:55Z","timestamp":1791218035205,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":510,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2000,8]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Simethicone, activated charcoal and antimicrobial drugs have been used to treat gas\u2010related symptoms with conflicting results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To study the relationship between gaseous symptoms and colonic gas production and to test the efficacy of rifaximin, a new non\u2010absorbable antimicrobial agent, on these symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Intestinal gas production was measured by hydrogen (H<jats:sub>2<\/jats:sub>) and methane (CH<jats:sub>4<\/jats:sub>) breath testing after lactulose in 21 healthy volunteers and 34 functional patients. Only the 34 functional patients took part in a double\u2010blind, double\u2010dummy controlled trial, receiving, at random, rifaximin (400\u2003mg b.d per 7\u2003days), or activated charcoal (400\u2003mg b.d per 7\u2003days). The following parameters were evaluated at the start of the study and 1 and 10\u2003days after therapy: bloating, abdominal pain, number of flatus episodes, abdominal girth, and cumulative breath H<jats:sub>2<\/jats:sub> excretion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Hydrogen excretion was greater in functional patients than in healthy volunteers. Rifaximin, but not activated charcoal, led to a significant reduction in H<jats:sub>2<\/jats:sub> excretion and overall severity of symptoms. In particular, in patients treated with rifaximin, a significant reduction in the mean number of flatus episodes and of mean abdominal girth was evident.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>In patients with gas\u2010related symptoms the colonic production of H<jats:sub>2<\/jats:sub> is increased. Rifaximin significantly reduces this production and the excessive number of flatus episodes.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2000.00808.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:41:50Z","timestamp":1047354110000},"page":"1001-1008","source":"Crossref","is-referenced-by-count":76,"title":["Non\u2010absorbable antibiotics for managing intestinal gas production and gas\u2010related symptoms"],"prefix":"10.1111","volume":"14","author":[{"given":"M.","family":"Di Stefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Strocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Malservisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Veneto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. R.","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"StrocchiA&LevittMD.Intestinal gas. In: Sleisenger MH Fordtran JS eds. Gastrointestinal Disease. Philadelphia: Saunders 1993: 1035\u201342."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(19)33654-6"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(98)02146-1"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197607292950507"},{"key":"e_1_2_6_6_2","first-page":"192","article-title":"Effects of orally administered activated charcoal on intestinal gas","volume":"75","author":"Hall RGJr","year":"1981","journal-title":"Am J Gastroenterology"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-1-61"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(85)90129-5"},{"key":"e_1_2_6_9_2","first-page":"A261","article-title":"Does activated charcoal relieve gas symptoms?\u2014a placebo controlled study","volume":"100","author":"White JG","year":"1991","journal-title":"Gastroenterology"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000200726"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528109182001"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90549-5"},{"key":"e_1_2_6_13_2","first-page":"107","article-title":"Bacterial fermentation of carbohydrates within the gastrointestinal tract","volume":"1","author":"Caspary WF","year":"1981","journal-title":"Clin Res Rev"},{"key":"e_1_2_6_14_2","first-page":"48","article-title":"L\/105, a new semisynthetic derivative of Rifamycin sv, synthesis and structure\u2013activity relationship","volume":"2","author":"Marchi E","year":"1983","journal-title":"Chemioterapia"},{"key":"e_1_2_6_15_2","first-page":"365","article-title":"In vitro activity of Rifaximin and Rifamycin against some anaerobic bacteria","volume":"6","author":"Lamanna A","year":"1984","journal-title":"Chemioterapia"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00348.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058801600410"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00751.x"},{"key":"e_1_2_6_19_2","first-page":"92","article-title":"Irritable bowel syndrome: guidelines for the diagnosis","volume":"2","author":"Thompson WG","year":"1989","journal-title":"Gastroenterol Internat"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)90884-8"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.6.662"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(87)90313-1"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0016-5085(86)90686-4","article-title":"Influence of the oropharyngeal microflora on the measurements of exhaled breath hydrogen","volume":"91","author":"Thompson DG","year":"1986","journal-title":"Gastroenterology"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/29.11.1980"},{"key":"e_1_2_6_25_2","first-page":"147","article-title":"Breath hydrogen (H2) response to carbohydrate malabsorption after exercise","volume":"102","author":"Payne DL","year":"1983","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_26_2","first-page":"789","article-title":"Modification of the breath hydrogen test: increased sensitivity for the detection of carbohydrate malabsorption","volume":"100","author":"Kotler DP","year":"1982","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_27_2","first-page":"695","article-title":"The possible role of breath methane measurement in detecting carbohydrate malabsorption","volume":"124","author":"Corazza GR","year":"1994","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115716"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197509112931103"},{"key":"e_1_2_6_30_2","first-page":"599","article-title":"A simple radiologic method to estimate the quantity of bowel gas","volume":"86","author":"Chami TN","year":"1991","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90145-3"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-4-199602150-00006"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00808.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00808.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2000.00808.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T14:01:36Z","timestamp":1698588096000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2000.00808.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["10.1046\/j.1365-2036.2000.00808.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00808.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]}}}